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Abstract As umbilical cord blood (UCB) is a rich source of
endothelial colony-forming cells (ECFC), our aim was two-
fold: (1) to examine potential obstetric selection criteria for
achieving the highest ECFC yields from UCB units, and (2) to
determine whether transient storage temperatures of fresh
UCB and cryopreservation of UCB units affected ECFC yield
and function. ECFC quality was assessed before and after
cryopreservation by their clonogenic proliferative potential.
Of the 20 factors examined, placental weight was the only
statistically significant obstetric factor that predicted ECFC
frequency in UCB. Studies on the effects of storage revealed
that transient storage of fresh UCB at 4C reduced ECFC
yield compared with storage at 22C, while cryopreservation
of UCB MNCs significantly reduced ECFC recoveries. To
our knowledge, this is the first demonstration that placental
weight and temperature of storage prior to processing or
culture have significant effects on ECFC frequency in UCB.
Our studies further support the evidence that cryopreservation
of UCB MNCs compromises ECFC recovery.
Keywords Umbilical cord blood  Endothelial progenitor
cells  Cryopreservation  Endothelial colony-forming
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Abbreviations
ECFC Endothelial colony forming cells
UCB Umbilical cord blood
MNC Mononuclear cell
CBB Cord blood bank
TNC Total nucleated cell content
HSC Hematopoietic stem cells
HPC Hematopoietic progenitor cells
DNase Deoxyribonuclease
Introduction
Umbilical cord blood (UCB) is increasingly used as an
alternative source of hematopoietic stem and progenitor
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cells (HSC/HPC) to bone marrow and mobilized peripheral
blood for HSC transplantation in both children and adults
[1, 2]. It has the advantage that it can be tissue typed,
screened for viral biomarkers, processed and banked,
especially ahead of urgent or directed transplants, without
the attrition rate that occurs with bone marrow donors [1–4].
Of note, a recent report states that strategic objectives for
the UK NHSBT Cord Blood Bank (CBB) are maximized
clinical benefits and inventory utilization where a feasible
target is 1% annual utilization of banked UCB units [5].
UCB and the umbilical cord itself have been reported to
contain other stem/progenitor cell types, including mesen-
chymal stem/stromal cells and endothelial progenitor cells
[late endothelial outgrowth cells or endothelial colony
forming cells (ECFC)]. These overall types may have the
potential to improve transplant outcomes when used in
conjunction with HSC [6, 7]. Although ECFC are found in
umbilical cord tissue (HUVEC) and UCB at higher levels
and with higher proliferative potential than in adult periph-
eral blood [8–10], factors affecting their yield and recovery
from neonatal sources are still not understood. In contrast,
since the first UCB HSC transplant in 1988 [11], a great deal
of knowledge has been acquired on the optimal selection of
UCB units for HSC transplantation [12, 13]. This is based on
obstetric factors (Table 1), total nucleated cell content
(TNC), CD34? cell count, HLA and blood group matching
of the recipient and donor plus processing, storage and
testing procedures. Other quality measurements such as
maternal HLA typing to assess the donor’s non-inherited
maternal HLA-antigens may also influence transplant suc-
cess [1, 2, 12]. Typically, UCB is collected from a wide
range of donors, held for a period of time (not exceeding
24–48 h) at 22 ± 2C prior to processing, and then cryo-
preserved under controlled rate freezing conditions and
stored long-term below -150C (as recommended by
international accreditation agencies such as FACT-Netcord)
[1, 2, 8]. Units are also analyzed before or after processing
for TNC, CD34? cell numbers and hematopoietic colony
forming units [1, 8, 12–14]. Obstetric factors that have
previously been reported to affect TNC and/or HSC/HPC
(CD34? cells and total CFU) content include birth and
placental weight, infant gender, parity of the mother,
nucleated red cell content, low venous pH, prolonged first
stage of labor and Apgar scores [quantifies the ability of the
infant to adapt to the extra uterine environment and hence a
measurement of the health of newborn infants at 1, 5 and
10 min post birth (Apgar1min, Apgar5min, Apgar10min) with
the normal Apgar score varying from 7 to 10].
It remains uncertain how this knowledge of UCB HSC/
HPC quality and storage affects the late endothelial out-
growth cell/ECFC content of UCB. A recent report indi-
cates that pre-term UCB units at 28–35 weeks of gestation
contain*fourfold more ECFCs than term UCB [15], yet no
other obstetric features were examined. Additionally,
studies on ECFC recovery after UCB cryopreservation are
conflicting, with Lin et al. [16] indicating that the outgrowth
endothelial cell content is not statistically different between
cryopreserved and fresh UCB mononuclear cells although
on average fewer were recovered after cryopreservation,
while Vanneaux et al. [17] recovered significantly fewer
ECFC from cryopreserved than from fresh UCB units.
In order to achieve optimal ECFC yields from UCB at
term deliveries, we set out to determine (1) how to best
select UCB donors based on obstetric factors, (2) whether
storage temperatures of UCB units using current standards
for UCB HSC/HPC of 22 ± 2C prior to processing was
superior to storage at 4C, and (3) whether ECFC content
was compromised following cryopreservation. As with
HSC/HPC transplants, an understanding of optimal donor
selection, short-term storage conditions of whole UCB
before processing and long-term storage conditions of
cryopreserved UCB may in the future enhance the efficacy
of UCB ECFC for therapeutic use.
Materials and methods
Materials
Wash buffer A consisted of Hank’s buffered salt solution
(HBSS) without calcium and magnesium (Lonza Biologics,
Slough, England) supplemented with 3 g/l sodium citrate
and 0.5% (v/v) Hyclone fetal calf serum (FCS; Thermo
Scientific, Loughborough, England). Wash buffer B con-
sisted of HBSS without calcium and magnesium (Lonza
Biologics). Growth medium (‘complete EGM-2’) com-
prised EBM-2 media supplemented with all components of
the SingleQuot Bullet Kit [hydrocortisone, human epider-
mal growth factor, human fibroblast growth factor-basic,
insulin-like growth factor-1, vascular endothelial growth
factor, ascorbic acid, heparin, gentamicin, 2% (v/v) FCS]
(Lonza Biologics) and then further supplemented with 8%
(v/v) Hyclone FCS and 1% (v/v) penicillin/streptomycin
(PAA Laboratories Ltd., Yeovil, England). Bovine DNase I
(Sigma–Aldrich Ltd., Poole, England) was prepared in
50% (v/v) glycerol, 5 mM CaCl2 in HBSS (pH 7.8) and
stored at -20C. ‘Thaw buffer’ consisted of growth media
with 10 U/ml DNase I. Forty eight- and 6-well tissue cul-
ture plates pre-coated with type-1 rat tail collagen were
purchased from BD Biosciences (Oxford, England). Other
cell culture vessels were from Corning (Lowell, MA,
USA), 0.5% (w/v) trypsin and 0.2% (w/v) EDTA (trypsin–
EDTA) from PAA Laboratories Ltd., 0.4% (w/v) trypan
blue from Invitrogen Ltd. (Paisley, Scotland) and FC
Receptor Blocking Reagent from Miltenyi-Biotec. (Berg-
isch-Gladbag, Germany). Unless otherwise specified,
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incubations were at 37C in a humidified incubator with
5% CO2 in air. Accuspin tubes containing Ficoll-Hist-
opaque-1077 (1.077 g/ml), Fungizone and all other mate-
rials were obtained from Sigma–Aldrich Ltd.
Umbilical cord blood collection
Fresh UCB was collected by the NHSBT Cord Blood
Resource team (Oxford, England) (termed ‘R&D UCB’)
with informed written consent from mothers at the John
Radcliffe Hospital, Oxford in accordance with Oxfordshire
Research Ethics Committee approval. These mothers were
over the age of 18, had uncomplicated births, screened
negative at the time of delivery for a range of infections
(e.g. HIV, HBV, HCV, syphilis), did not use illegal drugs
and were not delivering at prematurity (\36 weeks). Fur-
ther exclusion criteria were known genetic defects of the
baby (e.g. Down’s syndrome, Spina Bifida) due to the
requirement for diagnostic placental specimens and to
reduce maternal distress. Due to other research projects
taking place at this hospital, no pre-eclampsic mothers
donated to this study. UCB was collected directly from the
umbilical cord as soon as possible after delivery of the
placenta by needle cannulation into sterile UCB collection
bags containing 21 ml citrate phosphate dextrose antico-
agulant (MacoPharma Ltd., Twickenham, England). Cell
counts from a sample of UCB from the bag were analyzed
using a Sysmex total blood analyzer (Sysmex XE-2100,
Sysmex UK Ltd., Milton Keynes, England). Samples were
anonymised prior to being made available to researchers.
Obstetric observations were obtained from archived data
by the Oxford-Radcliffe Hospital Information Service by
certified staff not involved in the research.
Mononuclear cells (MNC) were isolated from UCB by
centrifugation on Ficoll-Histopaque (density 1.077 g/ml)
using Accuspin tubes as per the manufacturer’s instruc-
tions. The resulting buffy coat was resuspended in wash
buffer A and sedimented once at 4009g to remove Ficoll,
once at 2009g to reduce platelet contamination and finally
sedimented at 4009g. The resulting pellet was washed with
complete EGM-2 then sedimented at 2009g. R&D UCB
MNC were cryopreserved in Hyclone FCS containing 10%
(v/v) DMSO in Nunc cryovials using a Nalgene Mr. Frosty
cryopreservation chamber at -80C. After at least 4 h,
cryovials were transferred to the gas-phase of liquid
nitrogen storage.
UCB destined for banking for unrelated transplants is
stored by the NHSBT Cord Blood Bank (termed ‘CBB
UCB’). The UCB for this purpose was collected in
2004–2005 by methods similar to above and described in
detail elsewhere [4]. UCB processing was carried out within
24 h of UCB collection and differs from the R&D proce-
dure above in that whole UCB was volume reduced to
21 ml and depleted of plasma and erythrocytes using the
Biosafe Sepax system [3, 18]. The UCB buffy coat was then
cryopreserved using DMSO and stored in a BioArchive.
CD34? cells were enumerated by flow cytometry using the
ISHAGE protocol. The starting volumes and TNC of CBB
UCB units were similar to R&D UCB units (Table 2). Of
the UCB units used here, the majority were made available
for research because consent was specifically given to
donate to research but not banking (63%). Other reasons
were low TNC (5%) and failure to complete 12 week follow
up interviews necessary for banking (32%).
Recovery of MNC from cryopreservation
Cryopreservation vials were removed from gas-phase
liquid nitrogen, briefly stored in dry ice and then thawed
rapidly at 37C in a waterbath. Without delay, the volume
of thawed MNC volume was doubled over 1 min by
gradual drop-wise addition of warm (37C) thaw buffer
with gentle mixing. Five further volumes of warm thaw
buffer were then added, mixed gently and incubated at
37C for 30 min with DNase 1 in a sealed tube. Cells were
pelleted by centrifugation at 22C for 10 min at
2009g. Supernatant was aspirated (90% of total volume)
and cells resuspended by gentle pipetting.
Endothelial cell culture and enumeration of primary
endothelial colony forming cells
UCB MNCs were plated at 2 9 107 MNCs/well in 4 ml
complete EGM-2 into rat collagen 1-coated 6-well plates
and grown for 24 h at which time cultures were then
washed gently three times with wash buffer B to remove
unattached cells and debris, before feeding with complete
EGM-2. Growth medium was changed daily for six further
Table 2 Characteristics of
UCB
a CBB UCB units are volume
reduced to 21 ml for processing
whereas R&D UCB units are
not. Error is SEM
Characteristic CBB UCB R&D UCB
Volume (ml) 67 ± 5 89 ± 4
TNC 9 107 (/UCB unit) 82 ± 12 77 ± 1
MNC 9 106 (/ml) 39.4 ± 6.0a 8.1 ± 0.7
CD34? 9 106 (/UCB unit) 2.7 ± 0.8 n/a
n 19 30
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days, then every second day from d8 to d14. ECFC-derived
colonies based on those with endothelial morphology were
counted on d14 using light microscopy (Nikon Eclipse
TS100, Nikon Ltd., London, England) and contained
[50 cells/colony. ECFC frequency was enumerated in
three ways (A) per UCB unit, (B) per ml of UCB and
(C) normalized per 106 MNC seeded. At this time, these
primary colonies were defined as passage 0 (p0), and a
passage number incremented with each subsequent trypsi-
nation and subculture.
At d14, cultures were gently washed three times with
wash buffer B to remove all media and debris and individual
colonies isolated by incubation with trypsin–EDTA for
10 min or until completely detached. Where necessary to
avoid non-endothelial morphology cells (e.g. single
attached cells, striated cells), cloning rings were used to
isolate endothelial colonies. ECFC-derived colonies (on
average 10 per culture) were pooled and seeded into a T75
flask (75 cm2 surface area) in 30 ml of complete EGM-2.
When cells reached approximately 90% confluency, they
were subcultured again as follows. T75 flasks were washed
three times with 30 ml of Dulbecco’s phosphate wash
buffered saline (DPBS) (Lonza Biologics) to remove all
residual complete media and serum. Cells were incubated
with 3 ml trypsin–EDTA for 10 min or until they were
completely detached from the flask. Cells were split at a
dilution rate to give 90% confluency 4–5 days later. The
endothelial nature of the ECFC-derived cells was confirmed
by morphology and phenotypic analysis as described [19].
Proliferative potential of endothelial colony forming
cells
Proliferative potential of ECFC was measured in the clo-
nogenic endothelial colony-formation assay as described
previously [19]. Briefly, pooled p1 endothelial colonies
(d14) from each UCB harvest were pooled, diluted to give
0.5 cells/well by limiting dilution and manual pipetting in
collagen-coated 96-well plates in 100 ll complete EGM-2
and grown for 14 days with complete media replacement
every 3–5 days. On d14 colonies were examined micro-
scopically and by Calcein AM staining and scored. Primary
colonies were scored as previously described as high pro-
liferative potential (HPP) ([2,000 cells/colony), low pro-
liferative-potential (LPP) (50–2,000 cells/colony or
disregarded as endothelial clusters (\50 cells/colony) [19].
Statistical analyses
Statistical analysis of the effect of obstetric factors con-
sisted of transforming the data to give a normal distribu-
tion. In the generalized linear model, framework
discriminant analysis was carried out by fitting a binary
regression analysis using R statistical package. Other tests
of statistical significance were performed with the software
program, Prism (GraphPad, Version 5, San Diego, USA).
Results
Obstetric and demographic factors analyzed
Obstetric factors have proven useful as selection criteria
for UCB units for HSC transplantation. A similar
approach was taken here for assessing ECFC content in
UCB units in this study. Many factors are known about
the mother and baby before the delivery (prenatal), at the
time of the delivery (perinatally) and shortly after the
delivery at the time of UCB collection, selection and
processing (postnatally). Prenatal factors examined were
maternal parity, gravidity, age, ethnic group, sex of the
baby and gestation period. Perinatal factors examined
were the duration of labor and the stages of labor,
delivery method, route of delivery, weight of placenta,
birth weight, ethnic group of baby and Apgar scores at 1,
5 and 10 min. Post natal features of UCB were volume of
UCB, MNC concentration, TNC and nucleated red blood
cell concentration.
To test whether obstetric factors had an effect on ECFC
yield from UCB, ECFC were enumerated in 52 fresh R&D
UCB units collected at random. Demographic information
about the UCB donors is presented in Tables 3 and 4. Of
note, those collected for research purposes were dissimilar
to national averages for cord blood banking regarding route
of delivery, parity, gravidity, placental weight and ethnic-
ity. Of the deliveries, 27% were vaginal, 71% were
cesarean and 2% were a cesarean after first stage labor.
This statistic reflects the nature of UCB collection of UCB
units for research at the John Radcliffe Hospital, where
cesarean sections present the best prospect for collecting
UCB due to the increased opportunity for pre delivery
written informed consent, the relatively predictable time-
frame for delivery and availability of the placenta, and
lower frequency of damage to afterbirth tissues. Parity and
gravidity were higher than the national averages. Mean
placental weight exceeded the UK average for babies born
at term which is *545 g, and reflected the fact that the
majority of births were by cesarean section which tend to
result in higher placental weights [20]. Sixty-one percent of
babies were male, and 39% were female. Ninety percent of
births were from white Caucasoid mothers. Many other
demographic features were similar to the UK national
averages. Maternal age was similar to the UK national
average of 29.3 years [20] and neonatal weight was similar
to the average UK birth weight of approximately 3,400 g
[20]. As dictated by the scope of this study, all babies in
Angiogenesis (2011) 14:381–392 385
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this study were born at term with gestational age ranging
from 37 to 41 weeks. Only 3.3% of babies had an
Apgar1min score \ 7, indicating the majority of neonates in
this study were in overall good health.
Placental weight predicts ECFC content of UCB units
Table 5 summarizes the mean numbers and the range of
ECFC found in the 52 UCB units tested. ECFC-derived
cells were confirmed by morphology and phenotype as
endothelial in nature (Fig. 1). The range of ECFC fre-
quencies was from 0 to 375 ECFC/unit with 8 UCB units
not forming ECFC and with the mean ECFC numbers being
44.6 ± 9.8 ECFC/UCB unit or 8.2 ± 1.8 ECFC/108 MNC.
In testing the effect of obstetric factors, skewed data
were transformed by taking the Box-Cox transformation to
achieve an approximate normal distribution of the data and
to stabilize the variance, thereby satisfying the conditions
for a valid linear model. Some of the explanatory variables
were also transformed to remove excessive skewness. Fit-
ting of a linear model regression was then attempted for the
full data set (n = 52) initially using ECFC/UCB as a unit
of measurement of ECFC frequency. This was because, of
the three experimental outcomes examined for ECFC fre-
quency (per unit, per ml UCB, per 108 MNC), ECFC/UCB
unit responded best to transformation i.e. achieved the best
approximation of a normal distribution of the data. The
effect of multiple obstetric factors was examined starting
with all obstetric variables and the least significant vari-
ables eliminated from the modeling in a stepwise fashion.
Neither combination of the obstetric factors nor any single
factor exhibited a statistically significant causal relation-
ship with ECFC frequency/UCB unit. Similar outcomes
were obtained from the same analyses with ECFC/ml UCB
and ECFC/108 MNC.
An alternative modeling approach was taken by
excluding all UCB where EFCF/UCB unit = 0 and ana-
lyzing the remaining data using the approach above. With
the zeroes omitted, it was possible to find the optimal Box-
Cox transformation of the response variable, which had the
Table 3 Demographics of prenatal and perinatal maternal, obstetric
and neonatal observations of UCB donors
Characteristics (n) Range Number Percent (%)
Maternal age (years) (52) 18–25 8 15.4
26–35 30 57.7
35 14 26.9








Mode of delivery (48) Vaginal 13 27.1
Caesareana 35 72.9
Neonatal sex (49) Male 30 61.2
Female 19 38.8















Ethnic group (49) White 44 89.8
Other 5 8.2
a 34 caesarean without labor, 1 caesarean after 1st stage labor
Table 4 Demographics of
perinatal maternal, obstetric and
neonatal variables
Characteristics (n) Mean ± SD Range
Gestational age (weeks) (49) 39 ± 1 37–41
Neonatal weight (g) (49) 3427 ± 472 2,620–4,442
Placental weight (g) (46) 704 ± 144 450–1,100
Time between onset of stage 1 labor and onset of stage 2 labor (h) (13) 4.4 ± 0.7 1.3–9.2
Time between onset of stage 2 labor and delivery of the baby (h) (13) 0.8 ± 0.3 0.1–3.1
Time between delivery of the baby and end of stage 3 labor (h) (13) 0.2 ± 0.1 0.0–1.0
Table 5 Endothelial colony forming cell (ECFC) content of umbil-
ical cord blood units
Characteristics Mean ± SEM Range
ECFC/UCB unit 44.6 ± 9.8 0–375
ECFC/ml 0.5 ± 0.1 0–4.1
ECFC/MNC (9108) 8.2 ± 1.8 0–57.1
n = 52 UCB units
386 Angiogenesis (2011) 14:381–392
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form (Y^lambda - 1)/lambda, with lambda = 0.1. Pla-
cental weight (range 450–110 g) was the only statistically
significant predictor of ECFC frequency (P-value =
0.046). No other obstetric factor gave an indication of
having a significant effect (Fig. 2). The following formula
if Epred is predicted ECFC/cord blood unit and P is pla-
cental weight (g) was devised to predict the ECFC fre-
quency from placental weight.




The function is plotted in Fig. 2 along with 95% prediction
interval bands and the measured data points with placental
weights lower than 2,000 g have also been added. The
range of placental weights was restricted to being less than
2,000 g in order to avoid undue compression of the scale. It
is worth noting that the heavier placental weights in fact
turn out to lie almost exactly on the prediction curve.
Further, a discriminant analysis approach was taken by
awarding a binary variable to ECFC/UCB unit and a fit of a
generalized linear model attempted, i.e. UCB units which
gave rise to ECFC were awarded a value of one, and those
that did not were awarded a value of zero. As above, the
effect of multiple obstetric factors was examined starting
with all obstetric variables and the least significant vari-
ables eliminated from the modeling in a stepwise fashion.
By this method, neither combination of the obstetric factors
nor any single factor exhibited a statistically significant
causal relationship with ECFC frequency/UCB unit.
UCB storage temperatures affect ECFC yield
In addition to examining obstetric factors, we also assessed
if UCB storage temperature affected ECFC yield. Since, in
accordance with FACT-Netcord standards, we store fresh


























































Fig. 1 ECFC-derived cell characteristics. Representative photomi-
crographs of ECFC-derived colonies cultured from UCB MNCs on
a d9 of culture (94 magnification) and b d14 (910 magnification) of
culture. Colonies with similar cobblestone morphology were identi-
fied in other cultures of UCB. c Flow cytometric profile of ECFC-
derived cells. Representative graph of median fluorescence intensity
(MFI) ? SEM (n = 3) using cells from different donors. Antibody
isotypes and fluorophores are grouped to compare test antibody
staining with isotype control staining
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Blood Bank at 22 ± 2C after collection and do so for up
to 24 h before processing by volume reduction [18, 21], we
examined the effects of transient storage of UCB on ECFC
yield. R&D UCB units were collected from 25 subjects at
random and stored at either 4 ± 2C or 22 ± 2C in
temperature mapped fridges/incubators for 24 h, then the
‘Enumeration of ECFC’ procedure was followed as
detailed in the ‘‘Materials and methods’’.
The data were clearly non-normal and therefore a non-
parametric Wilcoxon rank sum test for location difference
was carried out with allowance for one pair of tied values
in the 4C group. The P-value was 0.0013 and it was
therefore concluded that there was a highly significant
difference between the two groups. Storage for 24 h at
22C yielded 4 times more ECFC/CBU than storage for
24 h at 4C (the ratio of medians was 4.07, the ratio of
means was 4.06) (Fig. 3).
The effect of cryopreservation on ECFC was also
examined by comparing ECFC yield from fresh R&D UCB
units with their recovery after cryopreservation. To test
recovery of ECFC from cryopreservation, MNC were iso-
lated from 20 R&D UCB units as per the ‘ECFC enu-
meration’ procedure in the ‘‘Materials and methods’’. At
the cell pellet stage, before seeding into a 6-well plate, the
MNC were split into two samples, one was cryopreserved
and the other tested for ECFC as per the ‘Enumeration of
primary Endothelial Colony Forming Cells’ procedure. The
cryopreserved sample was stored at -195C for 2–14 days,
and then thawed in the presence of DNase 1 which was
used to digest extracellular DNA from lysed neutrophils,
and viable MNC numbers determined. MNC were typically
[95% viable. Viable MNC were seeded as per the ‘Enu-
meration of Endothelial Colony Forming Cells’ procedure
and the resulting ECFC content of the cryopreserved UCB
compared with ECFC yield from fresh UCB. Ninety per-
cent of fresh R&D UCB samples generated ECFC com-
pared to 33% of the cryopreserved UCB samples. When the
latter 33% of UCB units that formed ECFC in both fresh
and frozen UCB samples were compared, the ECFC
recovery from cryopreservation was *50% lower than that
found in the original fresh UCB sample (Fig. 4b). The
Fig. 2 Correlation between placental weight and ECFC. Model fit
(solid line) of the correlation between placental weight and ECFC/
UCB unit (P \ 0.05), 95% confidence intervals are indicated by
dashed lines




















Fig. 3 Effects of short-term storage conditions on yield of ECFC.
UCB were stored for either 2 h at 4C (n = 6), 24 h at 4C (n = 9) or
24 h at 22C (n = 10). Error bars are SEM. ECFC yields were
assessed per a UCB unit, b ml UCB and c MNC (9106) seeded.
Wilcoxon statistical analysis showed that storage at 4C had a
significant effect on ECFC yield both for 2 and 24 h (*P = 0.0013)
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quality of ECFC was also investigated by examining the
proliferative potential of the ECFC-derived cells in a clonal
proliferation assay. Endothelial colonies derived from each
UCB MNC preparation before and after cryopreservation
from the previous experiment were pooled and cultured
(p2) and their content of ECFCs which formed colonies of
different sizes assessed in the clonogenic assay described
in ‘Proliferative potential’ in the Materials and Methods.
ECFC yield from CBB procedures were examined by
enumerating ECFC from cryopreserved CBB UCB units
and the results presented in Fig. 5. ECFC yield/ml UCB
was sixfold lower in CBB than cryopreserved R&D UCB
units indicating ECFC losses during CBB UCB processing
procedures (Fig. 5a). Interestingly, of those ECFC a
threefold higher proportion of these were high-proliferative
and a 1.4-fold higher proportion were low-proliferative.
The remainder (clusters and non-proliferative) was 1.2-fold
higher in R&D than CBB UCB (Fig. 5b). However these
findings conflict with the absolute levels of HPP and LPP
per volume of UCB (considering CBB UCB exhibited
sixfold lower ECFC/ml). Collectively these findings sug-
gest that, qualitatively and quantitatively, CBB and R&D
UCB units are comparable in terms of highly proliferative
cells. However, there may be the possibility of increasing
ECFC yields, and hence highly proliferative ECFC yields,
from CBB UCB units as indicated by ECFC/ml UCB.
In CBB UCB units, the relationship between CD34? cell
numbers and ECFC was examined by testing for a linear
correlation between CB34? cells per UCB unit and ECFC/
UCB unit (Fig. 5c). No correlation was observed (r2 =
0.1490) suggesting that CD34? cell content in UCB units
would not be good predictor of ECFC content.
Discussion
The therapeutic potential for ECFC for supporting blood
cell reconstitution, vascular engineering, neovasuclarisa-
tion and cardiovascular repair has been widely discussed
[8]. In order to fully realize the clinical utility of ECFCs
that are known to be present in UCB, we must first
understand factors affecting the yield of these cells from
UCB. The study presented here focused on whether
obstetric factors, transient pre-processing storage and long-
term cryopreserved storage could influence the ECFC
content of UCB at term, areas which have not previously
been fully investigated. Our results demonstrate a positive
correlation between placental weight and ECFC content of
UCB in the donor population studied. Previous studies
have shown that placental weight and weight of the infant
at birth positively correlate with TNC count, UCB volume,
CD34? cell content and total hematopoietic CFU in UCB
(Table 1). Indeed, Ballen et al. [22] have suggested that
Fig. 4 UCB ECFC recovery from cryopreservation. a Recovery of
ECFC from cryopreservation compared with yield from fresh UCB
(fresh n = 23, crpv n = 15, error bars are SEM). b Proliferative
potential of recovered ECFC from cryopreservation compared with
ECFC proliferative potential from fresh UCB (fresh n = 8, crpv
n = 3); crpv cryopreserved; LPP, low proliferative potential cells
[19]; HPP, high proliferative potential cells [19]
Fig. 5 UCB ECFC recovery from cryopreserved R&D and CBB
sources. a ECFC frequency in UCB (CBB n = 14, R&D n = 15, error
bars are SEM). b Proliferative potential of ECFC by source (CBB
n = 3, R&D n = 3). c ECFC frequency/cord blood unit versus CD34?
cells/UCB unit. CBB cord blood bank-sourced UCB units; R&D
research resource-sourced UCB units; CBU cord blood unit; LPP, low
proliferative potential cells; HPP, high proliferative potential cells
Angiogenesis (2011) 14:381–392 389
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each 500 g increase in birth weight contributes to a 28%
increase in CD34? cell counts.
However, CD34 has suggested to be both a hematopoi-
etic and endothelial progenitor and mature endothelial
marker [8–10], hence, it has been difficult to correlate
CD34? cell numbers in peripheral blood or UCB with
ECFC content in normal individuals. ECFCs are thought to
represent a minor proportion of the CD34? cells which do
not express CD45 [8, 15, 23, 24]. For the CBB UCB units
used here, the ISHAGE protocol for CD34? enumeration
reported total CD34?CD45dim which probably do not best
represent ECFC. Indeed, in the present study, we observed
no correlation between CD34? expressing cells and ECFC
frequency. Currently, UCB banks select UCB units for HSC
transplant based on CD34? cell content thresholds and the
requirement for maximal ethnic diversity. However, in light
of the current findings, UCB units reported as having low
CD34? content according to the ISHAGE protocol may still
be a useful source of ECFC and so should not be discarded.
We saw no correlations with many of the obstetric
factors examined including parity, mode of delivery or
infant gender. As the donor population was skewed
towards uncomplicated pregnancies and deliveries at term
from Caucasoid mothers, an analysis of a wider range of
Apgar scores, gestational ages and ethnicity on ECFC
content of UCB was not possible in our study. It was not
possible to analyze the effect of ethnic origin on ECFC
content of UCB in this study, yet this is a factor of par-
ticular relevance to UCB banking especially in the UK
where adult bone marrow registries lack ethnic diversity of
donors. Ethnicity has been shown to have no significant
effect on TNC in relation to HSC/HPC UCB banking and
transplantation [25] while Caucasoid births produce higher
UCB CD34? yields [26]. In those ethnic groups where
placental weight is lower than in white Caucasoid donors
[4], the ECFC numbers may well be lower than in term
UCB units from larger white Caucasoid donors.
Interestingly, our studies have allowed us to develop a
formula to predict the ECFC frequency from placental
weight with a 95% confidence interval for the predicted
value and this formula could be used in the future with
defined ethnic groups to confirm its robustness. Baker et al.
[15] have suggested that ECFC content and proliferative
ability in UCB may contribute to organogenesis in for
example the renal glomerulus and retina and the need to
significantly expand the pulmonary microvasculature dur-
ing late gestation and early post natal life. It would thus
seem reasonable to assume that the rate of development
may also correlate with the UCB content of ECFC and
proangiogenic hematopoietic cells, both of which have key
roles in neovasculogenesis [8, 24].
In addition to assessing obstetric factors, we also ana-
lyzed the effects of transient storage temperatures on ECFC
yield from UCB. Current FACT-Netcord standards support
transient storage and transport of UCB units for subsequent
HSC transplantation prior to processing at 22 ± 2C [1, 2,
4]. Our own practice at the NHS Cord Blood Bank is to
maintain UCB units at these temperatures for up to 24 h
before processing is initiated [27]. This is because initial
studies involving human HPCs demonstrated that UCB
storage at both 4C and room temperature for up to 24 h
led to little or no cell loss [29–31], with slightly higher
counts for UCB stored at room temperature [29] and so,
consensus is that there is no significant effect on TNC and
CD34? cell viability and hematopoietic CFU when UCB is
stored at room temperature for 24 h. However, storage
conditions for longer times are conflicting. Recent studies
[32] suggest that, with the exception of viable CD34? cells,
there is a significant decrease in TNC, MNC and CD45?
cell viability between 72 and 96 h and, with the exception
of viable CD34? cells and CFU-GM, the reductions are
significantly higher with room temperature as opposed to
4C storage pre-processing. Our studies revealed that we
could recover higher numbers of ECFC if UCB was stored
at 22 ± 2C as opposed to 4C storage for 24 h. Our
findings may be explained by the fact that storage at room
temperature instead of refrigeration avoids rapid cooling
and subsequent warming of the blood which leads to
temperature shock and can trigger cellular apoptosis [14].
To our knowledge, similar studies concerning ECFC
recovery have not been done.
In agreement with Vanneaux et al. [17], our studies
indicate that cryopreservation of UCB MNCs, even after
room temperature storage for up to 24 h, significantly
affected ECFC recovery. However, the quantity of HPP
ECFCs was less affected by cryopreservation than the
overall ECFC yield from UCB. If proliferative potential of
ECFC is of clinical importance in future therapeutic
applications, then indeed HPP ECFC yield is the more
important criteria.
As well as the limitations described above, this and
similar studies are also limited by the lack a specific bio-
marker for enumerating ECFC in UCB, particularly in light
of the lack of a correlation observed with CD34. An
important question from the clinical perspective is: ‘how
many ECFCs are required for a useful therapeutic dose?’
which raises the possibility of expanding and banking
ECFC from UCB as a further transplant option. We are still
some way from using banked UCB units as a source of
ECFCs in the clinic where they may promote hematopoi-
etic engraftment and tissue repair. However, UCB trans-
plantation and UCB banking are both rapidly evolving
fields and in future, any readily available information
regarding the efficacy of stem/progenitor cells in such units
may impact significantly on the quality of units selected for
transplantation and research. With this in mind, further
390 Angiogenesis (2011) 14:381–392
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studies on more diverse populations of donors are war-
ranted to fully determine which obstetric factors affect
ECFC numbers in UCB.
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